Fighting Omicron: This Covid Vaccine Candidate Is Going After The Dangerous Mutation

  • CureVac N.V.  CVAC and GSK plc GSK have started a Phase 1 trial of the modified COVID-19 mRNA vaccine candidate, administered as a booster dose to previous COVID-19 vaccination.
  • The candidate, CV0501, is meant to be administered as a booster dose following the previous COVID-19 vaccination. GSK used CureVac's "second-generation mRNA backbone" to develop the vaccine.
  • CureVac will test CV0501 in up to 180 healthy, COVID-19 vaccinated adults. The participants will receive a single booster dose in the dose range of 12µg to 50µg at first.
  • Related: BioNTech, Pfizer File For Clearance Over COVID-19 Vaccine Patent Dispute With CureVac.
  • Additional dose levels below 12µg and above 50µg may be evaluated if supported by safety and immunogenicity data at these dose levels.
  • In March, the company also kicked off a phase 1 test for a "second-generation" COVID-19 shot called CV2CoV.
  • The company said this double-pronged approach would help identify the best-performing candidate for later-stage clinical development.
  • Data from the two studies will be reported together, although CureVac did not say when. 
  • Price Action: CVAC shares are down 0.08% at $13.17, and GSK stock is down 1.92% at $34.04 on the last check Thursday.
  • Photo by Gerd Altmann from Pixabay
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLarge CapNewsHealth CareGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!